Catalog # 10-4925
SX-682

CAS# 1648843-04-2

[2-[[5-[(4-Fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid

Lot # JKM1274



SX-682 is a novel CXCR1/2 inhibitor (IC_{50}s: CXCR1 = 42 nM, CXCR2 = 20 nM)[1]. It displayed robust synergistic activity with immune checkpoint blockade against castration resistant prostate cancer.[2] It significantly reduced tumor burden in a $Pten^{fl/fl}/Lkb1^{fl/fl}$ mouse model of lung squamous cell cancer when used in combination with anti-PD1 therapy.[3] SX-682 significantly inhibited trafficking of neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) enhancing anti-PD1 immune checkpoint blockade, T cell-based immunotherapy, and NK-cell immunotherapy.[4,5]

1) Zebala *et al.* (2015), *WO2015/016938*
2) Lu *et al*. (2017), *Effective combinatorial immunotherapy for castration-resistant prostate cancer*; Nature **542** 728
3) Kargl *et al*. (2019), *Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC*; JCI Insight **4** e130850
4) Sun *et al*. (2019), *Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy*; JCI Insight **4** e126853
5) Greene *et al*. (2020), *Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models*; Clin. Cancer Res. **26** 1420

PHYSICAL DATA

Molecular Weight:	467.20
Molecular Formula:	$C_{19}H_{14}BF_4N_3O_4S$
Purity:	>98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (>25 mg/ml)
Physical Description:	Off-white solid
Storage and Stability:	Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462
www.focusbiomolecules.com